Sintx Technologies, Inc. SINT
Technologies is an advanced ceramics company formed in December 1996 that develops, manufactures, and commercializes silicon nitride
biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX provides biomedical
solutions for medical devices specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications.
We also manufacture parts made from silicon nitride for customers in the electrical, aerospace and other industrial sectors. SINTX is
Last close
1.63
2026-09-04
Market cap
$10.9M
2026-06-30 share count
52-week range
1.40 - 5.14
Valuation FY2025 figures against the last close
P/S10.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-6.16
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $2.9M | $2.6M | $1.6M | $606.0K | $594.0K | $689.0K | $95.0K | $11.2M | $15.2M |
| Cost of revenue | $557.0K | $811.0K | $784.0K | $265.0K | $449.0K | $475.0K | $551.0K | $56.0K | $6.4M | $3.8M |
| Gross profit | $461.0K | $2.1M | $1.8M | $1.3M | $157.0K | $119.0K | $138.0K | $39.0K | $4.9M | $11.4M |
| R&D | $4.6M | $5.2M | $8.7M | $6.5M | $5.9M | $4.8M | $3.4M | $3.0M | $3.5M | $6.3M |
| SG&A | $6.2M | $4.0M | $4.2M | $4.0M | $3.6M | $3.1M | $2.9M | $3.9M | $3.7M | $6.3M |
| Total operating expenses | $11.2M | $16.1M | $15.2M | $12.6M | $10.8M | $8.6M | $6.7M | $13.2M | $7.5M | $23.0M |
| Operating income | -$10.7M | -$14.0M | -$13.4M | -$11.3M | -$10.6M | -$8.5M | -$6.6M | -$13.1M | -$7.5M | -$11.5M |
| Pre-tax income | -$10.4M | -$11.0M | -$8.3M | -$12.0M | -$9.3M | -$7.0M | -$4.8M | -$9.7M | -$5.8M | -$14.8M |
| Net income | -$10.4M | -$11.0M | -$8.3M | -$12.0M | -$9.3M | -$7.0M | -$4.8M | -$8.7M | -$9.3M | -$14.8M |
| EPS, basic | -6.16 | -14.87 | -443.47 | -54.67 | -37.70 | -1.01 | -4.82 | -61.85 | -3.13 | — |
| EPS, diluted | -6.16 | -15.19 | -624.47 | -60.81 | -39.91 | -1.08 | -5.69 | -76.73 | -3.13 | -13.63 |
| Shares, diluted (wtd. avg.) | 2.8M | 744,782 | 21,786 | 317,323 | 250,701 | 17.4M | 1.6M | 383,855 | 3.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.1M | $3.6M | $3.3M | $6.2M | $14.3M | $25.4M | $1.8M | $5.4M | $539.0K | $6.9M |
| Receivables | — | — | — | — | — | — | — | $263.0K | $1.2M | $1.6M |
| Inventory | $825.0K | $502.0K | $888.0K | $737.0K | $597.0K | $487.0K | $639.0K | $676.0K | $675.0K | $7.2M |
| Total current assets | $5.7M | $4.5M | $5.5M | $7.2M | $15.0M | $27.6M | $4.1M | $7.0M | $3.7M | $16.0M |
| Property, plant and equipment | $476.0K | $922.0K | $4.8M | $5.7M | $4.0M | $471.0K | $190.0K | $124.0K | $218.0K | $889.0K |
| Goodwill | $302.0K | — | — | — | — | — | — | — | $6.2M | $6.2M |
| Other intangibles | $142.0K | $16.0K | $21.0K | $26.0K | $31.0K | $36.0K | $41.0K | $46.0K | $2.7M | $3.2M |
| Total assets | $9.5M | $9.4M | $15.4M | $15.8M | $21.8M | $30.4M | $9.1M | $11.5M | $14.6M | $26.3M |
| Accounts payable | $382.0K | $299.0K | $636.0K | $434.0K | $241.0K | $194.0K | $191.0K | $301.0K | $1.7M | $658.0K |
| Short-term debt | $7.0K | $32.0K | $46.0K | $160.0K | $509.0K | $109.0K | $6.0K | — | $605.0K | $7.0M |
| Total current liabilities | $3.7M | $2.0M | $2.9M | $8.1M | $2.7M | $2.9M | $2.1M | $2.4M | $8.3M | $14.0M |
| Long-term debt | — | — | — | $368.0K | — | $287.0K | $12.0K | — | $3.0M | $7.0M |
| Total liabilities | $6.6M | $5.5M | $6.6M | $10.1M | $4.6M | $4.6M | $3.9M | $3.1M | $9.2M | $15.0M |
| Retained earnings | -$292.1M | -$281.7M | -$270.7M | -$262.5M | -$250.4M | -$241.1M | -$234.1M | -$229.3M | -$220.6M | -$211.3M |
| Total equity | $2.9M | $3.9M | $8.8M | $5.7M | $17.2M | $25.8M | $5.2M | $8.4M | $5.4M | $11.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.6M | -$8.6M | -$14.1M | -$10.3M | -$10.1M | -$9.1M | -$6.4M | -$9.3M | -$4.7M | -$7.2M |
| Depreciation and amortisation | $319.0K | $842.0K | $907.0K | $335.0K | $185.0K | $78.0K | $102.0K | $105.0K | $105.0K | $1.4M |
| Stock-based compensation | $1.4M | $82.0K | $291.0K | $369.0K | $309.0K | $45.0K | $2.0K | $42.0K | $219.0K | $273.0K |
| Capital expenditure | $185.0K | $690.0K | $530.0K | $1.4M | $3.7M | $360.0K | $147.0K | $11.0K | $6.0K | $671.0K |
| Investing cash flow | $913.0K | -$194.0K | -$501.0K | -$1.1M | -$1.7M | $1.8M | $1.4M | -$145.0K | -$1.1M | -$617.0K |
| Financing cash flow | $8.2M | $9.1M | $11.7M | $3.3M | $705.0K | $30.9M | $1.4M | $14.4M | -$559.0K | $3.2M |
| Buybacks | $133.0K | — | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-011924.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $11.2M | $95.0K | $689.0K | $594.0K | $606.0K | $1.6M | $2.6M | $2.9M | $1.0M |
| Gross profit | $11.4M | $4.9M | $39.0K | $138.0K | $119.0K | $157.0K | $1.3M | $1.8M | $2.1M | $461.0K |
| Net income | -$14.8M | -$9.3M | -$8.7M | -$4.8M | -$7.0M | -$9.3M | -$12.0M | -$8.3M | -$11.0M | -$10.4M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |